|
Canada-0-CARTAGE Azienda Directories
|
Azienda News:
- Study Details | NCT05931484 | Study to Evaluate the Safety . . .
This is a phase 2, double-blind, multi-center, placebo-controlled clinical study to evaluate the safety, tolerability, efficacy, and PK of FHL-301 in adult patients with early-stage PD
- Trial | NCT05931484
This is a phase 2, double-blind, multi-center, placebo-controlled clinical study to evaluate the safety, tolerability, efficacy, and PK of FHL-301 in adult patients with early-stage PD Following screening, qualifying patients who meet all inclusion and exclusion criteria will enter the study and be randomized 1:1 to receive FHL-301 or Placebo at a starting dose of 200 mg BID (30 minutes
- Gemfibrozil in Parkinson Disease - Clinical Trials Registry - ICH GCP
A Phase 2, Double-Blind, Multi-Center, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of FHL-301 in Adult Patients With Parkinson's Disease
- Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 . . .
Phase 2 Not yet recruiting Conditions Parkinson Disease Interventions Drug: Placebo Drug: Gemfibrozil Feedback Registration Number NCT05931484 Lead Sponsor Forest Hills Lab Brief Summary
- Los Angeles Clinical Trial Study to Evaluate the Safety, Tolerability . . .
This is a phase 2, double-blind, multi-center, placebo-controlled clinical study to evaluate the safety, tolerability, efficacy, and PK of FHL-301 in adult patients with early-stage PD Following screening, qualifying patients who meet all inclusion and exclusion criteria will enter the study and be randomized 1:1 to receive FHL-301 or Placebo at a starting dose of 200 mg BID (30 minutes
- NCT05931484 - Study to Evaluate the Safety, Tolerability, Efficacy, and . . .
Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients
- Gemfibrozil - Drug Targets, Indications, Patents - Synapse
Following screening, qualifying patients who meet all inclusion and exclusion criteria will enter the study and be randomized 1:1 to receive FHL-301 or Placebo at a starting dose of 200 mg BID (30 minutes before the morning and evening meals) during the 3-week titration period
- Peripheral lipolysis inhib Trials - LARVOL Sigma
NCT05931484: Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients
- Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 . . .
This is a phase 2, double-blind, multi-center, placebo-controlled clinical study to evaluate the safety, tolerability, efficacy, and PK of FHL-301 in adult patients with early-stage PD
- Clinical Trial Highlights: Anti-Inflammatory and Immunomodulatory . . .
Gemfibrozil (FHL-301), currently used in lipid modification, has also entered phase 2 clinical trials in PD (NCT05931484)
|
|